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The	activation	of	type	I	IFN	signaling	is	a	major	component	of	host	defense	against	viral	infection,	but	it	is	
not	typically	associated	with	immune	responses	to	extracellular	bacterial	pathogens.	Using	mouse	and	human	
airway	epithelial	cells,	we	have	demonstrated	that	Staphylococcus aureus	activates	type	I	IFN	signaling,	which	
contributes	to	its	virulence	as	a	respiratory	pathogen.	This	response	was	dependent	on	the	expression	of	pro-
tein	A	and,	more	specifically,	the	Xr	domain,	a	short	sequence–repeat	region	encoded	by	DNA	that	consists	of	
repeated	24-bp	sequences	that	are	the	basis	of	an	internationally	used	epidemiological	typing	scheme.	Protein	
A	was	endocytosed	by	airway	epithelial	cells	and	subsequently	induced	IFN-β	expression,	JAK-STAT	signaling,	
and	IL-6	production.	Mice	lacking	IFN-α/β	receptor	1	(IFNAR-deficient	mice),	which	are	incapable	of	respond-
ing	to	type	I	IFNs,	were	substantially	protected	against	lethal	S. aureus	pneumonia	compared	with	wild-type	
control	mice.	The	profound	immunological	consequences	of	IFN-β	signaling,	particularly	in	the	lung,	may	
help	to	explain	the	conservation	of	multiple	copies	of	the	Xr	domain	of	protein	A	in	S. aureus	strains	and	the	
importance	of	protein	A	as	a	virulence	factor	in	the	pathogenesis	of	staphylococcal	pneumonia.
Introduction 
Staphylococcus aureus has reemerged as a major human pathogen, 
and in 2005, infection due to methicillin-resistant (MRSA) strains 
alone caused more than 18,000 deaths in the US, many acquired 
in the community by normal hosts. Staphylococcal pneumonia 
contributed to more than 75% of these deaths (1). Such invasive 
infections indicate successful bacterial exploitation of the immune 
system. While S. aureus has many gene products that directly inter-
act with diverse immune effectors, exactly how such devastating 
infections occur is not entirely clear. Local production of cytotoxin, 
such as the α-hemolysin (2), Panton-Valentine leukocidin (PVL) (3), 
and phenol soluble modulins (4), clearly contributes to pathology. 
However, none of these are uniformly expressed by these virulent 
isolates of S. aureus (5), suggesting that additional virulence factors 
must be important in the pathogenesis of these infections.
Staphylococcal protein A (SpA) is a conserved surface component 
of all S. aureus strains, consisting of an N-terminal IgG-binding 
domain, an Xr or short sequence–repeat region (SSR) encoded by 
variable numbers of 24-bp repeated DNA sequences, and a C-termi-
nal anchor to the bacterial cell wall (Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI35879DS1) (6). The amino terminus of SpA, the IgG-binding 
domain, activates tumor necrosis factor receptor 1 (TNFR1) (7) and 
EGFR (8), contributing substantially to the pathology induced by 
the inflammatory response evoked by S. aureus, and the SpA-TNFR1 
interaction has been shown to be essential in the pathogenesis of 
staphylococcal pneumonia (7). The Xr region provides the basis of 
the spa typing system and is generated by deletion, duplication, and 
point mutation of the repeated DNA sequences (9). This provides 
sufficient diversity to differentiate strains involved in clinical out-
breaks of infection from all over the world (10). However, despite 
their widespread conservation,  the  function of  these repeated 
sequences has been entirely unclear.
To explore the biological role of the Xr domain of SpA, we trans-
lated the DNA sequences of the repeats present in the most fre-
quent spa types and found that they encode highly conserved pep-
tides (Supplemental Figure 1B) with homology to LMP1 of EBV, 
the major oncoprotein of EBV and a potent activator of type I IFN 
signaling (11). The type I IFN cascade is a major immune effector 
critical for the systemic response to viral infection (12) and the 
coordination of innate and adaptive immune responses (13). Mice 
lacking components of the type I IFN signaling system (trif –/– and 
Ifnar–/–, where TRIF indicates TIR-domain-containing adapter-
inducing interferon-β and IFNAR indicates IFN-α/β receptor 1) 
are highly susceptible to viral infection but are afforded significant 
protection from endotoxin-mediated death (14, 15). Similarly, type 
I IFN production has been shown to increase host susceptibility to 
the Gram-positive obligate intracellular organism Listeria monocy-
togenes (16). This cascade has been associated with both pro- and 
antiinflammatory signaling through the activation of STAT1, 
STAT2, and STAT3 (17). In a number of inflammatory conditions, 
IFN-β downregulates many genes, including matrix metallopro-
teinases, chemokines, and adhesion molecules (18). While type I 
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IFN signaling can be activated by diverse microbial signals, a typi-
cal cascade involves TLR-mediated recognition of an intracellular 
microbial component, IRF3- and IRF7-mediated transcription of 
IFN-β, and, through an autocrine pathway, ligation of the IFN-α/β 
receptor IFNAR, which in turn stimulates tyrosine kinase 2 (Tyk2) 
and  the  JAK-STAT  cascade,  resulting  in  cell  type–dependent 
immune responses, including IL-6 production (19).
Having previously found that SpA readily activates IL-6 produc-
tion in airway cells (20), we postulated that S. aureus activates the 
type I IFN cascade and that SpA is involved. As the major mediators 
of the type I IFN cascade are well known, we focused on what we 
believe are the novel aspects of this hypothesis: how extracellular 
Gram-positive bacteria could induce signaling that has been previ-
ously associated with intracellular viral infection or mediated by 
LPS and TLR4 (15, 21, 22). We demonstrate that S. aureus, through 
the Xr domain of SpA, activates known components of the type 
I IFN cascade and that this contributes to the virulence of the 
organism as a respiratory pathogen.
Results
S. aureus USA300 activates type I IFN signaling in airway cells. S. aureus 
strain USA300  is a community-acquired methicillin-resistant 
strain now epidemic in the US (1). We tested the ability of this 
strain to induce type I IFN signaling	in murine airway epithelial 
cells in primary culture and used a spa-null mutant to determine 
the contribution of SpA in this process. A sharp increase in IFN-β 
transcription was detected following exposure to USA300 but 
not the spa mutant (100-fold at 2 hours and >400 fold at 4 hours) 
(Figure 1A). Induction of IFN-α family members was not detected. 
Production of IFN-β–dependent gene products was also observed: 
USA300 induced a 7-fold increase in Mx-1, a prototypical type 
I IFN antiviral effector, a 130-fold increase in IL-6, and a 4-fold 
increase in Lif, a gene product that is important in host defense in 
the lung specifically (23). Induction of these IFN-dependent gene 
products was significantly attenuated in the absence of SpA (Fig-
ure 1A). Induction of PKR transcription, important in the induc-
tion of apoptosis and sensitization of macrophages against the 
effects of LPS (24), was not observed (Figure 1A).
Production of IFN-β is followed by an autocrine pathway con-
sisting of activation of the common IFN-α/β receptor (IFNAR), 
phosphorylation of the transcription factors STAT1, STAT2, and 
STAT3 by JAK family kinases, and expression of more than 300 
type I IFN-dependent genes (25). We compared the activation of 
this cascade in murine airway cells in response to USA300 with 
that in response to a spa mutant. Both STAT1 and STAT2 became 
phosphorylated after exposure to USA300 (required for induction 
of IFN-β–dependent gene products such as Mx-1), coincident with 
IFN-β production. This phosphorylation was less pronounced in 
cells exposed to the spa-null mutant. Tyrosine phosphorylation 
of STAT3 was induced by both strains, indicating the presence of 
SpA-independent signaling mechanisms (Figure 1B). These data 
indicate that S. aureus potently induces the type I IFN cascade in 
airway epithelial cells and that much of this response is depen-
dent on expression of SpA.
Ifnar–/– mice are protected from S. aureus–associated mortality. The 
requirement for type I IFN signaling in the resolution of viral respi-
ratory infections has been well documented (12). However trif–/– 
and Ifnar–/– mice are protected from the lethal affects of endotoxin 
(14, 15). To determine whether staphylococcal activation of type I 
IFN signaling has similar negative consequences, WT (129/SvEv) 
and Ifnar–/– mice were intranasally infected with S. aureus USA300. 
The  Ifnar–/– mice were protected from lethal pneumonia with 
significantly reduced mortality, 10% as compared with 80% seen 
in the WT animals (P = 0.0055 by Fisher’s exact test; Figure 2A). 
Figure 
S. aureus strain USA300 induces type I IFN signaling in airway epithelial cells that is dependent on the expression of protein A. (A) Primary 
mouse airway epithelial cells were incubated with S. aureus USA300 or a SpA deletion mutant, and induction of IFN-β, Mx-1, IL-6, LIF, and PKR 
was detected by real-time PCR. Data are represented as fold increases over unstimulated controls and are representative of 3 independent 
experiments. *P < 0.05 as compared with the spa-null strain, Student’s t test. Error bars represent standard deviations. (B) p-STAT1, p-STAT2, 
and p-STAT3 were detected by immunoblot in primary airway epithelial cell cultures treated with USA300 (+) or spa-null (–). Corresponding total 
STATs are shown for loading controls.
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Using a 10-fold lower sublethal inoculum, we were able to compare 
the immune responses to USA300 in mice. There were no differ-
ences in either the levels of infection (Figure 2B) or the numbers of 
polymorphonuclear leukocytes (PMNs) recruited into the lungs of 
the Ifnar–/– and WT mice at either 4 or 24 hours after inoculation 
(Figure 2C). Although there was slightly more bacteremia found at 
4 hours in the Ifnar–/– animals (Figure 2B), this was less than a log 
difference, which was gone at 24 hours.
Figure 
Type I IFN signaling increases susceptibility to staphylococcal respiratory infection. Adult WT or Ifnar–/– mice were intranasally infected with (A) 
5 × 108 CFUs of S. aureus USA300 and mortality determined at 24 hours. *P = 0.0055, Fisher’s exact test; n = 10 mice per group. Mice were 
infected with 5 × 107 CFUs of S. aureus USA300 and at 4 and 24 hours after infection (B), bacterial loads were determined in lungs and spleens 
and lung suspensions and cells obtained by BAL fluid stained and analyzed by flow cytometry to enumerate (C) CD45+Gr1+ PMNs and (D) 
CD11c+CD11b+CD45+ DCs. Data are represented as percentage of total CD45 population. (E) TNF-α and IL-6 were detected in BAL fluid and 
blood by ELISA. Each point represents 1 animal; horizontal lines represent median values.
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The Ifnar–/– mice had significantly more CD11c+ DCs both in 
lung homogenates and bronchoalveolar lavage (BAL) fluid, which 
persisted from 4 to 24 hours (Figure 2D). At the same time points, 
the Ifnar–/– mice had significantly less TNF-α, and a trend toward 
less IL-6 in the BAL fluid compared with the WT animals (Figure 
2E). Systemic levels of TNF-α were minimal in both groups and at 
least an order of magnitude less than those detected in the BAL 
fluid (Figure 2E). These findings suggest that the major impact 
of type I IFN signaling in response to S. aureus is in the lung and 
involves the DC population and immune regulation.
The Xr domain of SpA activates IFN-β signaling. SpA has already been 
shown to be critical in the pathogenesis of pneumonia in a mouse 
model of infection (7). We next analyzed the contribution of each 
of the SpA subdomains in the activation of type I IFN responses 
Figure 
SpA is internalized and induces type 1 IFN signaling in airway epithelial cells. (A–E) Airway cells were incubated with SpA or SpA Xr and (A) 
internalization monitored by flow cytometry (ΔMFI, change in mean fluorescence intensity) or (B) by confocal microscopy for SpA (green) and 
transferrin (red) at 1 hour (original magnification, ×80). (C) SpA-induced IFN-β production was measured at 2 hours by real-time PCR in the 
presence of Dynasore (Dyn), (D) in response to transfection of an SpA Xr plasmid (Xr) or empty vector (CV), and (E) in the presence of 50 μg/ml 
polymixin B. (F) STAT1 and STAT3 phosphorylation in response to SpA (S) or LPS (L) after 1 and 2 hours was monitored in murine nasal epi-
thelial cells from WT or trif–/– mice. (G) STAT1 and STAT3 phosphorylation was monitored in airway cells in response to SpA Xr (30 min., n = 2; 
60 and 120 min., n = 3), in the presence of Dyn (n = 3), pan-JAK inhibitor (Pan, n = 3), JAK2 inhibitor (JAK2, n = 3), or neutralizing antibody to 
IFN-β (n = 2). Thin vertical lines between bands indicate data spliced together from original blot. Red arrows indicate that the same bands from 
the 120 min. Xr treatment were used as the control for pan-JAK and JAK2 inhibitor treatments. U, M, or Unstim. indicates unstimulated control. 
Unless otherwise indicated, data shows mean values of triplicate samples from 1 representative experiment out of 3, and error bars indicate 
standard deviations. *P < 0.001; **P < 0.05.
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in airway epithelial cells. The domains of SpA were subcloned to 
determine whether the Xr domain is both necessary and sufficient 
to activate the type I IFN response: namely, endocytosis of the 
ligand, IFN-β transcription, and JAK-STAT activation (Figure 3).
To determine whether SpA is endocytosed, we incubated fluo-
rescently labeled full-length SpA or a construct consisting of the 
Xr domain from strain Newman (which is virtually identical to the 
SpA of USA300) with human airway epithelial cells in primary cul-
ture and cell lines; after repeated washing and trypsin treatment 
to remove surface-associated SpA, we assayed for intracellular SpA 
(Figure 3A). Substantial internalization was detected by 1 hour of 
incubation and was significantly inhibited in cells maintained at 
4°C or treated with the dynamin inhibitor dynasore (26), suggest-
ing an endocytic process. Confocal imaging was consistent with 
accumulation of SpA in endosomes, as it colocalized extensively 
with transferrin (Figure 3B). Translocation of internalized SpA to 
the cytosol was assessed by incubating airway epithelial cells with 
a SpA–β-lactamase fusion protein and determining cytosolic β-lac-
tamase activity using a previously described reporter system (27). 
SpA did not translocate from the vesicles into the cytosol over the 
period of time studied (30 minutes to 4 hours) (data not shown).
Incubation of airway cells with SpA Xr for 2 hours induced IFN-β 
transcription; this induction of IFN-β transcription in response to 
SpA Xr was significantly blocked by dynamin inhibition (Figure 
3C). Since these constructs were synthesized as overexpressed pro-
teins in Escherichia coli, several control experiments were performed 
to exclude the possibility that contaminating LPS was affecting 
our experiments. As one control, we transfected airway cells with 
a plasmid expressing SpA Xr or a vector control and documented 
a 10-fold increase in IFN-β mRNA production as compared with 
that induced by the empty vector (Figure 3D). In addition, the 
recombinant Xr protein was pretreated with polymyxin B, which 
blocked LPS-induced IFN-β and Mx-1 production but not that 
stimulated by SpA Xr (Figure 3E).
The adaptor protein TRIF has been shown to be essential in 
coupling pattern recognition receptors to IFN-β signaling. We 
predicted that SpA-mediated activation of the pathway would be 
similarly TRIF dependent. STAT1 phosphorylation in response to 
either LPS or SpA was not observed in epithelial cells from trif–/– 
mice as compared with those from the WT controls (Figure 3F). 
STAT3 phosphorylation was only partially reduced in these ani-
mals, indicating that there are non-TRIF and non–IFN-β–depen-
dent pathways that elicit STAT3 activation. Thus, it appears that 
major components of the IFN-β pathway are activated both by LPS 
and SpA, although the specific receptor(s) and adaptor proteins 
remain to be identified.
Following IFN-β production, IFNAR was stimulated through 
an autocrine pathway, activating JAK-STAT signaling to initiate 
gene expression, which we monitored as STAT phosphorylation 
by the epithelial cells (28). Human airway epithelial cells incu-
bated with the SpA Xr domain exhibited dynamin-dependent 
tyrosine phosphorylation of STAT1 and STAT3, mediated by 
activation of JAK1 or Tyk2 but not JAK2 (Figure 3G), although 
considerable amounts of constitutive phospho-STAT3 were pres-
ent in unstimulated cells. Anti–IFN-β inhibited STAT1 but not 
STAT3 phosphorylation (consistent with the signaling through 
the gp130 receptors that utilize STAT3). STAT3 phosphorylation 
(Ser727) was detected in cells transfected with a vector encoding 
Figure 
SpA Xr induces IFN-β– and STAT3-dependent IL-6 production. (A) Airway epithelial cells in primary culture were stimulated with SpA Xr for the 
times indicated or for 2 hours in the absence or presence of dynasore, and IL-6 induction was detected by real-time PCR (black bars, left y axis) 
or ELISA (white bars, right y axis). Untreated cells or cells stimulated with SpA Xr were incubated with IFN-β–neutralizing antibody, and IL-6 
induction was measured by real-time PCR. IL-6 mRNA production is expressed as the fold induction compared with that of unstimulated cells. 
(B) Airway epithelial cells from WT or Stat1–/– mice were stimulated with SpA Xr in the absence (control) or presence of the inhibitors indicated, 
and IL-6 production was measured by real-time PCR. IL-6 induction is expressed as a percentage of that induced by SpA Xr in cells from WT 
mice. (A and B) Data represent the mean and SD of 3 wells from 1 representative experiment out of 3. *P < 0.05; **P < 0.001, Student’s t test 
performed on the raw data. Immunoblots demonstrating phosphorylation of STAT3 in airway cells from Stat1–/– mice and inhibition in the pres-
ence of STAT3 inhibitor are shown in B.
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full-length SpA or the Xr domain but not in airway cells express-
ing the SpA N terminus, indicating specificity for the Xr domain 
(Supplemental Figure 2A).
IL-6 production is a major product of JAK-STAT signaling, and 
epithelial IL-6 production contributes substantially to the patho-
physiology associated with staphylococcal infection. Cells in pri-
mary culture produced both IL-6 mRNA and protein in response 
to the Xr domain of SpA in a dynamin-dependent fashion, which 
was blocked by exposure to anti–IFN-β (Figure 4A). Cells trans-
fected with SpA Xr also produced IL-6 (Supplemental Figure 2B). 
The involvement of JAK-STAT signaling in IL-6 production was 
documented by monitoring responses in primary airway cells 
from Stat1–/– mice or WT primary mouse cells  treated with a 
STAT3 inhibitor (Figure 4B). The Stat1–/– cells and those treated 
with the STAT3 inhibitor did not produce IL-6 mRNA in response 
to Xr exposure (Figure 4B). STAT3 phosphorylation was intact 
in cells from the Stat1–/– animals in response to SpA Xr but sub-
stantially diminished in animals treated with the STAT3 inhibi-
tor (Figure 4B). These experiments indicate that both STAT1 and 
STAT3 are phosphorylated in response to SpA Xr and that both 
contribute to the production of IL-6.
To further document that IFN-β signaling occurs in vivo in 
response to staphylococcal infection, we demonstrated the phos-
phorylation of STAT1 and STAT3 in lung lysates from mice intra-
nasally inoculated with either S. aureus strain Newman or with 
the SpA Xr peptide alone (Figure 5A). Phosphorylation of STAT3 
at Ser727 was also activated in vivo in mice infected with WT 
S. aureus but not a protein A–null mutant (Supplemental Figure 3). 
IL-6 mRNA was significantly increased in the SpA Xr–treated mice 
and correlated with recruitment of PMNs into the lung. Both IL-6 
mRNA and PMNs were decreased in mice treated with the pan-
JAK inhibitor (Figure 5B). Mice treated with JAK inhibitor prior 
to and during S. aureus infection had much less IL-6 production 
than vehicle-treated animals (Figure 5C). The JAK inhibitor also 
appeared to affect bacterial clearance and PMN recruitment, but 
the effects were not statistically significant (Figure 5C).
Discussion
These studies indicate that extracellular Gram-positive bacteria 
activate the type I IFN cascade effectively and that this contributes 
to the morbidity and mortality associated with S. aureus respira-
tory infection. Protein A, already established as a major virulence 
factor in the pathogenesis of pneumonia by virtue of its ability to 
activate TNF signaling (7), also appears to be critical in the activa-
tion of IFN-β. It has been previously shown that protein A induces 
type I IFN in lymphocytes (29). The Xr domain of SpA, which 
consists of multiple 24-bp repeats of highly conserved peptides, 
appears to be both necessary and sufficient for IFN-β activation 
in airway epithelial cells. As protein A is abundantly shed from the 
surface of growing staphylococci, it seems highly plausible that 
this protein, even in the absence of intact organisms, is sufficient 
to activate the epithelial mucosa. This is of particular importance 
in the lung, where resident alveolar macrophages do not produce 
bioactive IFN-β (30). Note that the induction of IFN-β is in addi-
tion to other SpA functions, such as IgG-Fc binding that thwarts 
opsonization, binding to von Willebrand factor (31), and activa-
tion of TNFR1 and EGFR, all of which have been mapped to the 
N-terminal IgG-binding region (8).
Figure 
SpA Xr activates STAT1/3 in vivo. (A) C57BL/6 mice were intranasally inoculated with SpA Xr, S. aureus, or PBS (control). 4 hours later, p-STAT1 
(Tyr701), p-STAT3 (Tyr705), and β-actin were detected in lung lysates by immunoblot. Data from 2 representative mice out of 6 are shown for 
both left quadrants and bottom right quadrant. Data from 2 representative mice out of 3 are shown for top right quadrant. The thin vertical line 
between bands within a group indicate data spliced from the original blot. (B) IL-6 mRNA in the lung of SpA Xr–treated mice was detected by 
real-time PCR, and the percentage of PMNs among total leukocytes in the lung was determined by flow cytometry following intranasal inoculation 
of SpA Xr in untreated or JAK inhibitor–treated mice (Inh). Each dot represents an individual mouse, and horizontal lines show the median value 
in each group. (C) IL-6 mRNA in the lung of S. aureus–infected mice was detected by real-time PCR. The median values of the percentage of 
PMNs corresponding to those mice are shown.
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Many  details  of  the  SpA-activated  IFN-β  signaling  cascade 
remain to be defined. While we demonstrate dynamin-dependent 
endocytosis of SpA and the involvement of the TRIF adaptor, the 
specific intracellular receptor, perhaps a TLR, remains to be identi-
fied. The downstream components of a typical IFN-β cascade pre-
viously shown to be activated by LPS are similarly stimulated by 
S. aureus. Whereas STAT3 activation seems to be independent of 
the cascade initiated by IFN-β, it is required for the downstream 
effects of IFN-β–induced STAT1, such as IL-6 production.
Type I IFN signaling appears to have an important role in the 
pathogenesis of staphylococcal pneumonia: Ifnar–/– mice had dra-
matically increased survival as compared with WT mice infected 
with S. aureus USA300. As has been shown in murine models of 
respiratory viral infection, potent type I IFN stimulation causes 
significant loss of CD11c+ cells from the lung and appears to have 
an important role in immunoregulation in the airways (32, 33). 
The WT mice had significantly more TNF-α in their airways than 
Ifnar–/– mice, and we have previously demonstrated that TNF-α 
signaling is associated with substantial pulmonary pathology in 
response to S. aureus (7). Unexpectedly, neither PMN accumula-
tion in the airways nor sepsis was associated with the increased 
mortality of the WT mice. Several reports have documented that 
DCs and macrophages are highly sensitive to the effects of the 
type I IFNs. Consistent with our findings, in the absence of type 
I IFNs, recruited DCs are retained within the lung (34) and there 
is a failure to prime macrophages to secrete TNF-α (35). Exactly 
which component of the IFN-β cascade activated by S. aureus is 
directly responsible for the increased mortality observed in the 
mouse model is not yet known but could represent a target for 
therapeutic intervention.
The central role of the type I IFN in the host defense against 
viral infection has been well documented and is implicated in the 
pathogenesis of several bacterial infections (16, 23, 36). The many 
consequences of this cascade and its importance in linking the 
innate and adaptive immune response are the subject of numer-
ous reviews (12, 22). Exactly how bacterial products activate type I 
signaling remains to be established for most pathogens. Nor is 
it clear whether the type I IFN responses are beneficial for the 
host or the pathogen. TLR4 signaling initiated by LPS is clearly a 
major activator of type I IFNs; both IFN-β– and Tyk2-null mice 
are resistant to endotoxemia (21). In the case of Bacillus anthracis, 
type I IFN signaling also appears to convey a protective response 
to the host. For other Gram-positive pathogens, Streptococcus 
pneumoniae and Group B streptococci, induction of type I signal-
ing was important for bacterial clearance, and in these studies, 
in contrast with our findings, Ifnar–/– mice had persistent bac-
teremia and could not control the infection (35). More recent 
studies suggest that Group B streptococcus DNA is responsible 
for induction of type I IFN in mouse macrophages, although the 
proximal portions of this signaling system and the specific recep-
tors involved have yet to be identified (36).
Our data indicate that S. aureus similarly activates type I IFNs 
and that this has a detrimental effect on the ability of the host 
to handle S. aureus pulmonary infection. The local induction 
of type I IFN in response to influenza similarly might create 
a milieu conducive to staphylococcal superinfection, a major 
cause of postinfluenza mortality (37). While we have not identi-
fied all of the components of the pathway, S. aureus protein A, 
which interacts with several eukaryotic receptors, is the ligand 
involved. Moreover, the heterogeneous Xr region or SSR of pro-
tein A is required for type I IFN activation. As the Xr region is 
a site of active mutation, it is tempting to speculate that the 
impetus for deletion and duplication in the Xr domain is in 
some ways related to the immune pressure exerted by type I IFN 
effectors. Activation of type I IFNs in the lung enhances suscep-
tibility to S. aureus infection, and this well-characterized path-
way could provide an attractive target for immunomodulatory 
therapy for pneumonia.
Methods
Bacteria and recombinant proteins. S. aureus 6390, USA300, and clinical iso-
lates  were  grown  in  Casamino  Acids–yeast  extract–glycerophosphate 
(CYGP) broth, and E. coli was grown in Luria-Bertaini (LB) broth. The spa 
deletion mutant was generated with in-frame deletion of the target gene 
by allelic replacement, using the temperature-sensitive plasmid pMAD. 
USA300 is erythromycin resistant; therefore, we built a modified pMAD 
vector by cloning the kanamycin resistance gene from pFOU into the NaeI 
site of pMAD. In brief, about 1 kb PCR products upstream and down-
stream of targeted sequences were generated and ligated by gene splicing 
by overlap extension. The resulting 2-kb product was digested, gel purified, 
cloned into pMAD using the same restriction sites, and transformed into 
E. coli. Colony PCR was performed on E. coli transformants. Plasmids from 
positive clones were verified by digestion analysis and then used to trans-
form S. aureus RN4220, selecting for kanamycin-resistant and blue colo-
nies at 30°C. Plasmid from RN4220 was sequenced and used to transform 
S. aureus strain USA300, for which the gene was to be deleted. The pro-
cess of allelic replacement was described previously (38). Chromosomal 
deletion was verified by PCR and DNA sequencing. The resulting deletion 
strain was devoid of all protein A sequence and exhibited growth charac-
teristics similar to those of the parental strain.
The full-length spa and the fragment encoding the C-terminal region 
of SpA (SpA Xr) from S. aureus Newman have been previously cloned 
into pGEX-KG (39). Glutathione-S-transferase (GST) fusion recom-
binant proteins harboring 1 and 8 SSRs were similarly generated by 
cloning the C-terminal region of SpA from clinical isolates (spa type 
515 and 131, respectively; Supplemental Table 1) into pGEX-KG. For 
expression of recombinant SpA or SpA Xr, overnight cultures of E. coli 
BL21 containing the p-GEX-KG–SpA constructs were inoculated into 
fresh medium and grown to an OD600 of 0.5. Isopropyl β-D-1-thioga-
lactopyranoside (IPTG) was added to a concentration of 1 mM, and the 
culture was grown for a further 6 hours. Cells were harvested by centrif-
ugation at 8,000 g for 10 minutes in a Sorvall GS-3 rotor. The pellet was 
resuspended in PBS containing protease inhibitors (Roche), lysozyme 
(200 μg/ml), and DNase I (3 μg/ml). Cells were lysed by repeated freeze/
thaw cycles. Cell debris was removed by centrifugation. Recombinant 
proteins expressed from pGEX-KG contained an N-terminal GST fusion 
of 26 kDa. The GST fusion proteins were purified using the MicroSpin 
GST purification module (Amersham Biosciences; GE Healthcare) and 
dialyzed against PBS.
Cell lines and primary cultures. 1HAEo– and 16HBE, human airway epi-
thelial cell lines (D. Gruenert, California Pacific Medical Center Research 
Institute, San Francisco, California, USA), were grown as previously 
detailed (40, 41). Primary small airway epithelial cells (SAEC; Lonza) 
were grown in a polarized fashion on semipermeable supports and used 
between passage 2 and 3. Mouse airway epithelial cells, which have very 
low endogenous activation of STATs, were used throughout the study 
unless indicated. Cells were isolated from the nasal septum from indi-
cated strains of adult mice and grown in primary culture in a polarized 
fashion as previously described (42). trif –/– mice were a gift of Ira Tabas 
at Columbia University.
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The effect of biochemical inhibitors was tested by pretreating the cells 
for 30 minutes with dynasore (80 μM, synthesized by H. Pelish and pro-
vided by T. Kirchhausen, Harvard University, Boston, Massachusetts, USA), 
25 μM JAK inhibitor I  (Pan JAK inhibitor, Calbiochem), 50 μM JAK2 
inhibitor (Calbiochem), and 20 μM STAT3 inhibitor (Calbiochem). Dur-
ing stimulation, inhibitors were replenished in the medium. To block the 
effects of contaminating LPS, recombinant proteins were incubated with 
polymixin B sulfate (50 μg/ml; Sigma-Aldrich) for 1 hour prior to stimula-
tion. For depletion of IFN-β and IL-6, respective neutralizing antibodies 
were used at 2 × 104 U/ml (R&D Systems).
Internalization studies. For flow cytometry, cells were incubated with 
Alexa Fluor 488–conjugated full-length protein A (Molecular Probes; 
Invitrogen)  or  Alexa  Fluor  488–conjugated  SpA  Xr  (Protein  Label-
ing Kit; Molecular Probes, Invitrogen) for various periods of time at 
37°C or 4°C. Cells were washed 3 times and trypsin added for 30 min-
utes to remove surface-bound protein A. Cells were washed, and the 
remaining intracellular fluorescence was measured by flow cytometry 
(FACSCalibur, BD). For confocal microscopy, 16HBE cells were grown on 
Transwell-Clear filters (Costar; Corning) with an air-liquid interface to 
form polarized monolayers. Cells were incubated with Alexa Fluor 488–
conjugated protein A (Molecular Probes; Invitrogen) and Alexa Fluor 
546–conjugated transferrin (Molecular Probes; Invitrogen) for 1 hour. 
After washing, cells were fixed with 4% paraformaldehyde, and filters 
were removed from wells and mounted with VECTASHIELD (Vector 
Laboratories) onto glass slides.
β-lactamase TEM-1 reporter assay. GST-SpA was cloned into the pCX241 
vector, and the resulting GST-SpA–TEM-1 fusion protein was purified 
as described above and used to stimulate airway epithelial cells. At differ-
ent time points (30 minutes; 1, 2, 3, and 4 hours) cells were loaded with 
CCF2/AM (Invitrogen) and the percentage of blue fluorescent cells was 
determined by microscopy. Fluorescence was also quantified using a fluo-
rescence reader as previously described (26).
Real-time PCR. RNA was  isolated using the QIAGEN RNeasy Mini 
Kit and subjected to DNase treatment per the manufacturer’s instruc-
tions (QIAGEN). cDNA was made from 1 μg of RNA using the iScript 
Synthesis Kit (Bio-Rad). For quantitative real-time PCR, amplification 
was performed with Power SYBR Green Master Mix in a Step One Plus 
Thermal Cycler (Applied Biosystems). The following primers were used 
for amplification: mouse IFN-β, 5′-AGACTATTGTTGTACGTCTCC-
3′ and 5′-CAGTAATAGCTCTTCAAGTGG-3′; mouse Mx-1, 5′-TGTG-
CAGGCACTATGAGGAG-3′ and 5′-ACTCTGGTCCCCAATGACAG-3′; 
mouse PKR, 5′-GCACCGGGTTTTGTATCGA-3′  and 5′-GGAGCAC-
GAAGTACAAGCGC-3′; mouse  IL-6, 5′-TGATGCACTTGCAGAAAA-
CAA-3′   and  5′-GGTCTTGGTCCTTAGCCACTC-3′ ;   mouse  LIF, 
5′-TCTTCCCATCACCCCTGTAAATG-3′ and CTTGATCTGGTTCAT-
GAGGTTGC-3′;  mouse  actin,  5′-CCTTTGAAAAGAAATTTGTCC-3′ 
and 5′-AGAAACCAGAACTGAAACTGG-3′; human IFN-β, 5′-CTTG-
GATTCCTACAAAGAAGC-3′ and 5′-CATCTCATAGATGGTCAATGC-3′; 
human IL-6, 5′-AAGAGTAACATGTGTGAAAGC-3′ and 5′-CTACTCT-
CAAATCTGTTCTGG-3′; and human actin, 5′-GTGGGGCGCCCCAG-
GCACCA-3′ and 5′-CGGTTGGCCTTGGGGTTCAGGGGGG-3′. Forty 
cycles were run with denaturation at 95°C for 15 seconds, annealing at 
55°C for 30 seconds, and extension at 60°C for 45 seconds. β-Actin was 
used as control for standardization.
Intracellular expression of protein A. 1HAEo– cells were  transfected by 
nucleofection according to manufacturers  instructions (Amaxa) with 
a pCMV-FLAG vector encoding FLAG fusions of full-length SpA, the 
N-terminal region of SpA (containing the 5 IgG-binding domains) or the 
C-terminal region of SpA (SpA Xr). For confocal microscopy, 48 hours 
after transfection, cells were fixed with 4% paraformaldehyde, permeabi-
lized with 0.3% Triton X-100, and stained for FLAG and phospho-STAT3 
(Ser727; Cell Signaling Technology).
Western blot. Cells were lysed using 60 mM n-octyl-β-D-glucopyranoside 
in TBS (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.8) containing Complete Mini 
Protease Inhibitor Tablets (Roche), 1 mM sodium orthovanadate, 100 mM 
sodium fluoride, and 20 μM GM6001. Proteins were separated on 4%–12% 
Bis-Tris NuPAGE gels (Invitrogen), transferred to PVDF Immobilon-P 
Membrane (Millipore), and blocked with 5% milk in TBST (Tris-buffered 
saline plus Tween) (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween) for 
1 hour at room temperature. Immunodetection was performed using 
p-STAT1 (Y701; Cell Signaling Technology), p-STAT2 (Y689; Millipore), 
p-STAT3 (Y705; Cell Signaling Technology), STAT1 (Cell Signaling Tech-
nology), STAT2 (rabbit polyclonal obtained from C. Schindler at Colum-
bia University), STAT3 (Cell Signaling Technology), and β-actin (Sigma-
Aldrich)  antibodies  followed  by  secondary  antibodies  conjugated  to 
horseradish peroxidase (Santa Cruz Biotechnology Inc.).
IL-6 detection. 1HAEo– cells, weaned from serum for 24 hours, or mouse 
primary airway epithelial cells were exposed to the stimulus indicated, 
and IL-6 in the supernatant was measured by ELISA. IL-6 antibody pairs 
(Pierce Endogen; Thermo Scientific) were used for detection of human 
IL-6 (1HAEo– cells), and IL-6 DuoSet (R&D Systems) was used for detec-
tion of mouse IL-6.
Mouse studies. C57BL/6 mice (7 to 10 days old) were intranasally inocu-
lated with 10 μl of S. aureus (108 CFUs), an S. aureus protein A–null strain 
(108 CFUs) (43), the C-terminal region of SpA (SpA Xr, 50 μM), or PBS 
(control). 6- to 8-week-old Ifnar–/– or 129/SvEV mice were anesthetized 
with 100 mg/kg ketamine and 5 mg/kg xylazine and intranasally inocu-
lated with 107 or 108 CFUs S. aureus strain USA300. Mice were sacrificed 
at 24 hours after bacterial infection by overdose of pentobarbital. BAL 
fluids were obtained by instillation of 3 × 1 ml HBSS into the trachea 
of euthanized animals and centrifugation at 180 g for 10 minutes. For 
immune cell identification, cell suspensions were obtained from lung 
homogenates or BAL fluid and red cells were lysed. Remaining cells were 
suspended in PBS containing 10% normal mouse serum and incubated 
for 30 minutes at 37°C. Cells were then stained with combinations of 
PE-labeled  anti-CD45,  FITC-labeled  anti-Ly6G  (BD  Biosciences  — 
Pharmingen), PE-Cy5.5–labeled anti-CD11b (eBioscience), and APC-
labeled anti-CD11c (eBioscience)  in the presence of mouse Fc block 
(2.4G2; BD Biosciences — Pharmingen) and normal mouse serum. Nega-
tive control samples were incubated with irrelevant, isotype-matched 
antibodies. Cells were gated based on their forward scatter/side scatter 
profile and analyzed for the double expression of CD45 and Ly6G for 
PMNs. DCs were identified by double staining for CD11c and CD11b 
within the CD45+ population. For IFN-β and IL-6 mRNA quantification, 
mouse lungs were obtained at 16–18 hours after inoculation and stored 
in RNAlater (QIAGEN). Bacterial counts in lungs and spleens were deter-
mined by plating serial dilutions on CYGP-agar plates. IL-6 and TNF-α in 
the BAL fluid were detected by sandwich ELISA (R&D Systems and eBio-
science, respectively). All animal studies were approved by the Institute 
of Comparative Medicine at Columbia University.
Immunofluorescence staining of mouse lung sections. Mouse  lungs were 
inflated  with  and  fixed  overnight  in  4%  paraformaldehyde  before 
embedding  in paraffin. 5 μM serial  sections were deparaffinized  in 
xylenes, rehydrated, subjected to antigen retrieval, permeabilized in 
0.3% Triton X-100, and blocked in 5% normal goat serum before stain-
ing with antibodies to p-STAT3 (S727) or total STAT3. Primary antibod-
ies were revealed by Alexa Fluor 647–conjugated secondary antibodies 
(Invitrogen). Imaging was performed on a Zeiss LSM 510 META scan-
ning confocal microscope and analyzed using LSM Image Browser soft-
ware (version 4.2).
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Statistics. Samples with normal distribution were analyzed using a 2-tailed 
Student’s t test. Samples that did not follow normal distributions were analyzed 
with the nonparametric Mann-Whitney test. Mortality studies were subjected 
to Fisher’s exact test. P values less than 0.05 were considered significant.
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